Evidence map›Paper›PMID 35368213›Full record

ArticleCellular and molecular life sciences : CMLS2022

Protrudin regulates FAK activation, endothelial cell migration and angiogenesis.

Amita Arora, Annukka M Kivelä, Ling Wang, Rimante Minkeviciene, Juuso H Taskinen, Birong Zhang, Annika Koponen, Jing Sun, Michiko Shirane, You Zhou and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Host angiogenic reprogramming byFrontiers in microbiology · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Amita AroraMinerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Annukka M KiveläMinerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Ling WangCentre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.
Rimante MinkevicieneMinerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Juuso H TaskinenMinerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Birong ZhangSystems Immunity Research Institute, Cardiff University School of Medicine, Cardiff University, Cardiff, UK.
Annika KoponenMinerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Jing SunSystems Immunity Research Institute, Cardiff University School of Medicine, Cardiff University, Cardiff, UK.
Michiko ShiraneDepartment of Molecular Biology, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, Japan.
You ZhouSystems Immunity Research Institute, Cardiff University School of Medicine, Cardiff University, Cardiff, UK.
Pirta HotulainenMinerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Camilla RaiborgCentre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.
Vesa M OlkkonenMinerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, 00290, Helsinki, Finland. vesa.olkkonen@helsinki.fi.ORCID http://orcid.org/0000-0001-5553-7997
Minerva Foundation · FICardiff University · GBOslo University Hospital · NONagoya City University · JPUniversity of Helsinki · FI

Funding

Academy of Finland 285223Academy of Finland 307735Academy of Finland 322647Magnus Ehrnroothin Säätiö 0Sigrid Juséliuksen Säätiö 0Sydäntutkimussäätiö 0
6 · The paper itself

Abstract

During angiogenesis, endothelial cells form protrusive sprouts and migrate towards the angiogenic stimulus. In this study, we investigate the role of the endoplasmic reticulum (ER)-anchored protein, Protrudin, in endothelial cell protrusion, migration and angiogenesis. Our results demonstrate that Protrudin regulates angiogenic tube formation in primary endothelial cells, Human umbilical vein endothelial cells (HUVECs). Analysis of RNA sequencing data and its experimental validation revealed cell migration as a prominent cellular function affected in HUVECs subjected to Protrudin knockdown. Further, our results demonstrate that knockdown of Protrudin inhibits focal adhesion kinase (FAK) activation in HUVECs and human aortic endothelial cells (HAECs). This is associated with a loss of polarized phospho-FAK distribution upon Protrudin knockdown as compared to Protrudin expressing HUVECs. Reduction of Protrudin also results in a perinuclear accumulation of mTOR and a decrease in VEGF-mediated S6K activation. However, further experiments suggest that the observed inhibition of angiogenesis in Protrudin knockdown cells is not affected by mTOR disturbance. Therefore, our findings suggest that defects in FAK activation and its abnormal subcellular distribution upon Protrudin knockdown are associated with a detrimental effect on endothelial cell migration and angiogenesis. Furthermore, mice with global Protrudin deletion demonstrate reduced retinal vascular progression. To conclude, our results provide evidence for a novel key role of Protrudin in endothelial cell migration and angiogenesis.

Indexed as

Neovascularization, PathologicNeovascularization, PhysiologicAnimalsCell MovementFocal Adhesion Protein-Tyrosine KinasesHumansHuman Umbilical Vein Endothelial CellsMiceVesicular Transport ProteinsFocal Adhesion Protein-Tyrosine Kinasesprotrudin protein, mouseVesicular Transport ProteinsEndosomesFocal adhesion kinasemTORVasculatureZfyve27

Identifiers

PMID35368213
PMCPMC8977271
OpenAlexW4224998226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.